- Home
- SFWL vs MNOV Comparison
SFWL vs MNOV Comparison
Compare SFWL & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFWL | MNOV |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 72.7M |
| IPO Year | 2023 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SFWL | MNOV |
|---|---|---|
| Price | $0.92 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 20.1K | ★ 91.9K |
| Earning Date | 08-27-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.68 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $540,461,000.00 | $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | ★ 21.10 | N/A |
| 52 Week Low | $0.56 | $1.13 |
| 52 Week High | $1.29 | $2.06 |
Technical Indicators
Market Signals| Indicator | SFWL | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 66.96 |
| Support Level | $0.91 | $1.43 |
| Resistance Level | $0.99 | $1.52 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 93.59 |
Price Performance
Historical ComparisonAbout SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.